A little more than a month after Bay Area-based Freenome snagged $300 million in a Series D financing round, the company scored an additional $290 million from an investment made by Swiss pharma giant Roche.

Roche said on December 24 that the U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) to the company’s COVID-19 at-home rapid test that can be used by people as young as 14.

JP Morgan

J.P. Morgan Chase put an end to the uncertainty surrounding its annual health care conference, announcing that the 40th edition will move to a virtual format.

Roche

Roche announced promising results for the company’s anti-TIGIT checkpoint inhibitor tiragolumab in PD-L1-positive metastatic non-small cell lung cancer.

Roche

The shares of Utah-based Recursion climbed on December 7 after the company announced entering into a “transformational collaboration” with Swiss pharma giant Roche valued in the billions of dollars to identify and develop up to 40 new medications for neuroscience and oncology.

Roche and Atea Pharmaceuticals are terminating their partnership to develop and commercialize a Covid-19 antiviral effective February 10, 2022.

Novartis

For the past 20 years, Novartis has held a 33 percent stake in Roche, the company’s Basel, Switzerland neighbor. Now, Novartis has divested the Swiss drugmaker’s one-third stake to Roche for $20.7 billion.

Roche

Roche is launching a new genomic profiling kit that lets cancer researchers explore tumors without having to send tissue samples to centralized laboratories, the Swiss drugmaker said on Oct. 25.

Atea Pharmaceuticals Inc.’s experimental Covid-19 antiviral pill being developed with Roche failed to help patients with mild and moderate Covid-19 in a small study of mostly low-risk patients, driving the Boston-based drugmaker’s shares down more than 65 percent on Oct. 19.

Roche’s Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Oct. 13